Target intelligence / Profile preview

Talin–integrin beta cytoplasmic tail interface (Talin–β-integrin interface) (Talin–β-integrin interface)

Target
Talin–β-integrin interface
Molecular classification
Protein-protein interaction, Cytoskeletal protein complex, Cell adhesion molecule complex
01

Overview

The Talin–β-integrin interface is a critical protein-protein interaction (PPI) site responsible for the "inside-out" activation of integrin receptors (Nature Reviews Molecular Cell Biology, 2009). Talin, a large cytosolic protein, binds via its F3 phosphotyrosine-binding (PTB)-like domain to the cytoplasmic tail of the β-integrin subunit, specifically at the NPxY motif (UniProt, 2024). This binding event triggers a conformational change in the integrin's extracellular domain, shifting it from a low-affinity to a high-affinity state for ligand binding (Science, 2007). This process is fundamental to cell adhesion, migration, and mechanotransduction across various cell types, including platelets and leukocytes (Journal of Cell Science, 2013). In pathology, over-activation or overexpression of this interface contributes to thrombus formation, tumor metastasis, and inflammatory disorders (Blood, 2007; Cancer Research, 2011). Consequently, the Talin–β-integrin interface has emerged as a promising therapeutic target for developing PPI inhibitors, such as the small molecule mP13, which can modulate integrin activity more selectively than traditional extracellular antagonists (Journal of Medicinal Chemistry, 2014).

Other names
Talin–integrin beta cytoplasmic tail interactionTalin-FERM–integrin tail complexTalin-1–ITGB3 interfaceTalin-1–integrin beta-3 interaction
02

Mechanism of action

Inhibition of the protein-protein interaction between the Talin F3 domain and the β-integrin cytoplasmic tail, preventing inside-out integrin activation (Science, 2007; Journal of Medicinal Chemistry, 2014).

03

Biological functions

Integrin activationCell adhesionMechanotransductionCell migrationSignal transduction
04

Disease associations

CancerThrombosisInflammationFibrosis
05

Safety considerations

Risk of hemorrhage (Blood, 2007)Impaired wound healing (Journal of Cell Science, 2013)Potential for immunosuppression (Nature Reviews Molecular Cell Biology, 2009)
06

Interacting drugs

mP13

1 more in the full profile.

07

Biomarkers

Integrin activation status (e.g., PAC-1 binding) (PubMed, 2014)Talin-1 expression levels (Cancer Research, 2011)β3-integrin phosphorylation (UniProt, 2024)

Beyond the preview

Go deeper on Talin–integrin beta cytoplasmic tail interface (Talin–β-integrin interface) (Talin–β-integrin interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Talin–integrin beta cytoplasmic tail interface (Talin–β-integrin interface) (Talin–β-integrin interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call